Mostrar el registro sencillo del ítem
Imatinib use in the management of a patient with Doege–Potter syndrome
dc.contributor.author | Paz-Ibarra, Jose | |
dc.contributor.author | Lu-Antara, Jose | |
dc.contributor.author | Uscamayta, Brenda-Erendida | |
dc.contributor.author | Martinez-Auris, Jhancy | |
dc.contributor.author | Valencia-Rivera, Miriam | |
dc.contributor.author | Sáenz-Bustamante, Sofía | |
dc.contributor.author | Delgado-Rojas, Marialejandra | |
dc.contributor.author | Salcedo-Vasquez, Julia | |
dc.contributor.author | Concepción-Zavaleta, Marcio | |
dc.date.accessioned | 2023-09-11T21:24:49Z | |
dc.date.available | 2023-09-11T21:24:49Z | |
dc.date.issued | 2023-04 | |
dc.identifier.uri | https://hdl.handle.net/20.500.13053/9303 | |
dc.description.abstract | “Doege–Potter syndrome (DPS) is a paraneoplastic syndrome characterized by nonislet cell tumor hypoglycemia due to a solitary fibrous tumor, which produces insulin-like growth factor II. In this report, we present the case of a 67-year-old male with recurrent and refractory hypoglycemia due to DPS successfully treated with imatinib. He initially presented with neuroglycopenic symptoms and dyspnea secondary to a giant tumor in the left hemithorax, which was totally resected. During follow-up, 7 years later, he presented with thoracoabdominal tumor recurrence associated with severe hypoglycemia and underwent subtotal tumor resection, with a subsequent improvement of symptoms. The following year, he had a recurrence of his intra-abdominal tumor, which was unresectable, associated with severe hypoglycemia refractory to dextrose infusion and corticosteroids, thus receiving imatinib with a favorable response. The clinical presentation, diagnostic approach, progression of the disease, and response to treatment with imatinib in the management of a patient with large, recurrent, and unresectable mesenchymal tumors with insulin-like growth factor-2 secretion causing hypoglycemia highlight the importance of this case report“ | es_PE |
dc.format | application/pdf | es_PE |
dc.language.iso | eng | es_PE |
dc.publisher | BioScientifica Ltd. | es_PE |
dc.rights | info:eu-repo/semantics/openAccess | es_PE |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | es_PE |
dc.subject | Doege–Potter, Solitary fibrous tumor | es_PE |
dc.title | Imatinib use in the management of a patient with Doege–Potter syndrome | es_PE |
dc.type | info:eu-repo/semantics/article | es_PE |
dc.identifier.doi | 10.1530/EDM-22-0360 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_PE |
dc.publisher.country | GBR | es_PE |
dc.subject.ocde | 3.03.00 -- Ciencias de la salud | es_PE |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(es)
-
SCOPUS [380]